Physician profile
Sumit Gaur
NPI 1609972801
$3,203.75
in general payments reported to CMS, 2019-2025
26 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $129 · 2021: $62.10 · 2022: $78.63 · 2023: $624 · 2024: $1,895 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,280 · Food and Beverage: $842 · Consulting Fee: $350 · Grant: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Food and Beverage | $841.83 |
| Consulting Fee | $350.00 |
| Grant | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,441.57 | 2019-2025 | |
| Pfizer INC. | $376.94 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $335.04 | 2024 | |
| Gilead Sciences, INC. | $187.80 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $160.14 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $129.40 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $99.00 | 2020 | |
| Janssen Biotech, INC. | $57.30 | 2021-2024 | Erleada, Akeega, Balversa |
| Array Biopharma INC | $53.43 | 2022-2024 | Mektovi, Braftovi, Tukysa |
| Puma Biotechnology, INC. | $45.25 | 2021-2025 | |
| Astellas Pharma US INC | $36.09 | 2019 | |
| Incyte Corporation | $31.20 | 2023 | Jakafi |
| Taiho Oncology, INC. | $27.34 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $26.16 | 2019 | |
| Daiichi Sankyo INC. | $23.80 | 2023 | Enhertu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.74 | 2024 | Verzenio |
| Amgen INC. | $22.56 | 2023 | Lumakras |
| Elekta, INC. | $21.84 | 2019 | |
| Genzyme Corporation | $18.33 | 2019 | |
| Tempus Ai, INC | $17.52 | 2024 | |
| Seagen INC. | $17.36 | 2023 | Adcetris |
| Adaptive Biotechnologies Corporation | $15.91 | 2023 | Clonoseq |
| Tactile Systems Technology INC | $12.79 | 2023 | Entre Plus, Flexitouch Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $12.04 | 2019 | |
| Verastem, INC. | $11.20 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Gaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.